KURA - Kura Oncology - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

104.7M

Cash

477M

Avg Qtr Burn

-27.26M

Short % of Float

14.67%

Insider Ownership

1.76%

Institutional Own.

-

Qtr Updated

06/30/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Tipifarnib Details Head and neck cancer, Cancer, Head and neck squamous cell carcinoma	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tipifarnib Details Cancer, T-cell lymphoma, Lymphoma	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ziftomenib (menin inhibitor) (KO-539) Details Acute myeloid leukemia	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tipifarnib + alpelisib Details Head and neck cancer, Head and neck squamous cell carcinoma, Cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KO-2806 (FTI inhibitor) Details Solid tumor/s, Non-small cell lung carcinoma	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ziftomenib + venetoclax/azacitidine (ven/aza) or cytarabine/daunorubicin Details Blood cancer, Acute myeloid leukemia	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KO-2806 (FTI inhibitor) + cabozantinib Details Solid tumor/s, Renal cell carcinoma	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ziftomenib + gilteritinib Details Acute myeloid leukemia	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.